nach oben

Pediatric Surgery International

Erschienen in:

04.01.2021 | Original Article

Immunohistochemical staining of phosphorylated-ERK in post-chemotherapeutic samples is a potential predictor of the prognosis of neuroblastoma

verfasst von: Tomoko Tanaka, Yuichi Togashi, Yuki Takeuchi, Mayumi Higashi, Shigehisa Fumino, Tatsuro Tajiri

Erschienen in: Pediatric Surgery International | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The majority of relapsed neuroblastomas have mitogen-activated protein kinase (MAPK) pathway activating mutations. We previously showed the in vitro and in vivo anti-tumor effects of MAPK/ERK kinase (MEK) inhibitors in MAPK-activated neuroblastoma. We herein assessed the correlation between MAPK activation and the prognosis in neuroblastoma patients using phosphorylated extra-cellular signal-regulated kinase (pERK) immunohistochemistry to establish the protocol for the clinical administration of MEK inhibitors.

Methods

Neuroblastoma samples from patients treated in our hospital were immunostained with pERK. The clinical outcomes were retrospectively collected from medical records. The correlation between pERK positivity and the prognosis was analyzed.

Results

Regarding pre-chemotherapeutic specimens, there were no differences in the pERK status between tumors with a good and bad prognosis in both the nuclei and cytoplasm. Regarding post-chemotherapeutic specimens, one of eight tumors with a good prognosis and four of six tumors with a poor prognosis showed pERK-positive nuclear staining (p = 0.0909) and five of eight tumors with a good prognosis and four of six tumors with a poor prognosis showed pERK-positive cytoplasmic staining (p > 0.9999).

Conclusion

These findings suggested post-chemotherapeutic—not pre-chemotherapeutic—nuclear pERK-positive neuroblastoma tends to be associated with a poor prognosis and may be a potential therapeutic target for MEK inhibitor treatment.

Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA (2016) Neuroblastoma Nat Rev Dis Primers 2:16078. https://doi.org/10.1038/nrdp.2016.78CrossRefPubMed

Greengard EG (2018) Molecularly targeted therapy for neuroblastoma. Children (Basel). https://doi.org/10.3390/children5100142CrossRef

Cañete A (2020) High-risk neuroblastoma: where do we go? Ann Oncol 31(3):326–327. https://doi.org/10.1016/j.annonc.2019.12.003CrossRefPubMed

Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Ne P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM (2015) Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet 47(8):864–871. https://doi.org/10.1038/ng.3333CrossRefPubMedPubMedCentral

Tanaka T, Higashi M, Kimura K, Wakao J, Fumino S, Iehara T, Hosoi H, Sakai T, Tajiri T (2016) MEK inhibitors as a novel therapy for neuroblastoma: their in vitro effects and predicting their efficacy. J Pediatr Surg 51(12):2074–2079. https://doi.org/10.1016/j.jpedsurg.2016.09.043CrossRefPubMed

Takeuchi Y, Tanaka T, Higashi M, Fumino S, Iehara T, Hosoi H, Sakai T, Tajiri T (2018) In vivo effects of short- and long-term MAPK pathway inhibition against neuroblastoma. J Pediatr Surg 53(12):2454–2459. https://doi.org/10.1016/j.jpedsurg.2018.08.026CrossRefPubMed

Wang H, Zhang Y, Yun H, Chen S, Chen Y, Liu Z (2017) ERK expression and its correlation with STAT1 in esophageal squamous cell carcinoma. Oncotarget 8(28):45249–45258. https://doi.org/10.18632/oncotarget.16902CrossRefPubMedPubMedCentral

Mawrin C, Diete S, Treuheit T, Kropf S, Vorwerk CK, Boltze C, Kirches E, Firsching R, Dietzmann K (2003) Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol 23(3):641–648PubMed

Pelloski CE, Lin E, Zhang L, Yung WKA, Colman H, Liu J-L, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG, Fuller GN, Aldape KD (2006) Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in Glioblastoma. Clin Cancer Res 12(13):3935–3941. https://doi.org/10.1158/1078-0432.Ccr-05-2202CrossRefPubMed

10.

Holck S, Nielsen HJ, Pedersen N, Larsson L-I (2015) Phospho-ERK1/2 levels in cancer cell nuclei predict responsiveness to radiochemotherapy of rectal adenocarcinoma. Oncotarget 6(33):34321–34328. https://doi.org/10.18632/oncotarget.5761CrossRefPubMedPubMedCentral

11.

Smith ER, Cai KQ, Smedberg JL, Ribeiro MM, Rula ME, Slater C, Godwin AK, Xu XX (2010) Nuclear entry of activated MAPK is restricted in primary ovarian and mammary epithelial cells. PLoS ONE 5(2):e9295. https://doi.org/10.1371/journal.pone.0009295CrossRefPubMedPubMedCentral

12.

Smith ER, Smedberg JL, Rula ME, Xu XX (2004) Regulation of Ras-MAPK pathway mitogenic activity by restricting nuclear entry of activated MAPK in endoderm differentiation of embryonic carcinoma and stem cells. J Cell Biol 164(5):689–699. https://doi.org/10.1083/jcb.200312028CrossRefPubMedPubMedCentral

13.

Schulte M, Köster J, Rahmann S, Schramm A (2018) Cancer evolution, mutations, and clonal selection in relapse neuroblastoma. Cell Tissue Res 372(2):263–268. https://doi.org/10.1007/s00441-018-2810-5CrossRefPubMed

Titel: Immunohistochemical staining of phosphorylated-ERK in post-chemotherapeutic samples is a potential predictor of the prognosis of neuroblastoma
verfasst von: Tomoko Tanaka
Yuichi Togashi
Yuki Takeuchi
Mayumi Higashi
Shigehisa Fumino
Tatsuro Tajiri
Publikationsdatum: 04.01.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Surgery International / Ausgabe 2/2021
Print ISSN: 0179-0358
Elektronische ISSN: 1437-9813
DOI: https://doi.org/10.1007/s00383-020-04806-w

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Immunohistochemical staining of phosphorylated-ERK in post-chemotherapeutic samples is a potential predictor of the prognosis of neuroblastoma

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Pädiatrie

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Update Pädiatrie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Histological features of complete tracheal rings in congenital tracheal stenosis

Prophylactic innominate artery transection to prevent tracheoinnominate artery fistula: a retrospective review of single institution experiences

Risk factors influencing ascending testis after laparoscopic percutaneous extraperitoneal closure for pediatric inguinal hernia and hydrocele

Risk factors and outcomes of bile leak after laparoscopic surgery for congenital biliary dilatation

Thoracoscopic surgery for congenital lung cysts: an attempt to limit pulmonary resection in cases of lesions involving multiple lobes

Differences in post-operative complications after reconstruction for congenital biliary dilatation in a single institution-Roux-en-Y hepaticojejunostomy versus hepaticoduodenostomy -

Neu im Fachgebiet Pädiatrie

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Update Pädiatrie